News Breaks |
|
|
| October 10, 2012 |
| 05:50 EDT |  | GSK | Aeras signs agreement with GlaxoSmithKline to jointly advance TB vaccine
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis, or TB, vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant. This novel research and resource-sharing agreement between the largest non-profit TB vaccine biotech and one of the world's leading research-based pharmaceutical and healthcare companies marks advancement in the race to develop new vaccines against TB, a global infectious disease killer. The new agreement comes after promising results from early stage clinical trials showed that the GSK TB vaccine candidate known as M72/AS01E has an acceptable safety and reactogenicity profile and demonstrated an immune response. Under the new agreement, Aeras and GSK will each provide resources to run a multi-center proof of concept clinical trial to test the vaccine candidate in healthy adults between 18 and 50 years of age. The Phase IIb trial is scheduled to begin in Kenya, India and South Africa next year pending approvals from authorities. |
|
|
News For GSK From The Last 14 Days Check below for free stories on GSK the last two weeks. |
|
|
| June 18, 2013 |
| 08:37 EDT |  | GSK | Drug companies turn to microchips to test medicines, WSJ reports
 Subscribe for More Information |
|
| 07:13 EDT | | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information |
|
| 07:07 EDT | | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen
GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. |
|
| June 12, 2013 |
| 19:54 EDT | | GSK | GlaxoSmithKline investigates bribe claims in China, WSJ says
Subscribe for More Information |
|
| 07:16 EDT | | GSK | GlaxoSmithKline fires head of R&D in China, WSJ says
GlaxoSmithKline has fired it's head of R&D in China after finding that he had incorporated "misinterpreted" data in a paper he helped write for a journal, Nature Medicine, according to The Wall Street Journal, citing the company. Reference Link |
|
| June 6, 2013 |
| 15:59 EDT | | GSK | FDA votes for modified restrictions on GSK's Avandia, Reuters says
Subscribe for More Information |
|
| 15:42 EDT | | GSK | FDA panel revote reaffirms modified restrictions for GSK's Avandia, Reuters says
|
|
| 15:26 EDT | | GSK | FDA advisers say Glaxo Avandia vote may have been inaccurate, Bloomberg says
Advisers plan to take a break to assess problem with vote tally and plan to re-vote on GSK's Avandia after break, Bloomberg says. |
|
| 15:20 EDT | | GSK | FDA panel votes to modify market restrictions for Avandia, Reuters says
Subscribe for More Information |
|
| June 5, 2013 |
| 07:45 EDT |  | GSK | FDA to host a joint committee meeting
Joint Meeting of the Endocrinilogic & Metabolic Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee where the discussion on both days will be on GlaxoSmithKline's New Drug Application (NDA) 21071 for AVANDIA (Rosiglitazone Maleate) tablets is being held in FDA Offices in Silver Spring, Maryland on June 5-6 beginning at 8 am. Webcast Link |
| |
|
|
|
|
